RenovoRx, Inc.
RenovoRx, Inc. is a U.S.-based life sciences company focused on developing and commercializing targeted drug-delivery solutions for difficult-to-treat cancers. Its core product is RenovoCath, an FDA-cleared local delivery device used to deliver therapeutic agents directly to tumor sites, alongside an ongoing clinical program centered on its TAMP technology platform.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueStandalone sales of the RenovoCath delivery device to hospitals and cancer centers.
Development activities tied to the TAMP platform and related clinical studies.
Device supply used in post-marketing registry and investigator-led study settings.
Customers
RenovoRx sells primarily to hospitals, cancer treatment centers, and academic oncology institutions that use RenovoCath in interventional oncology procedures. Its early customer base includes high-volume centers, academic medical centers, and National Cancer Institute-designated centers that adopt the device for difficult-to-treat cancers and may reorder as clinical familiarity grows.
Buy RenovoCath for direct use in oncology procedures where targeted local delivery is needed.
Adopt the device for specialized interventional oncology cases and early clinical experience.
Use RenovoCath in advanced cancer care settings and contribute to broader clinical validation.
Purchase devices for use in TIGeR-PaC and post-marketing registry studies.
Strategy
RenovoRx is focused on expanding RenovoCath from an early commercial launch into a broader oncology device franchise by targeting high-volume cancer centers and encouraging repeat orders. It is also using clinical and registry activity to build evidence, expand awareness, and support future adoption, while keeping the commercial model capital-efficient through a small sales footprint and potential partnerships.
Recurring device sales are the main path to building a revenue base.
Clinical familiarity and data can support broader physician adoption.
A lean sales structure helps preserve resources while demand develops.
Geography
RenovoRx is headquartered in the United States and its commercial activity is centered in the U.S. oncology market. The company also relies on U.S.-based manufacturing through Medical Murray, its primary third-party RenovoCath manufacturer, which ties supply continuity to domestic production capacity.
Risks
RenovoRx faces the risks typical of an early commercial medtech and life sciences company, including limited operating history, uncertain physician adoption, and dependence on a narrow product set. Its results also depend on successful manufacturing, reimbursement and purchasing dynamics at hospitals, and the ability to convert clinical interest into sustained commercial demand.
- Limited operating history as a revenue-generating companyImpact: HighLikelihood: High
The company has only recently begun commercial sales, so future demand and execution are unproven.
Exposure: RenovoCath commercialization
- Dependence on a single product platformImpact: HighLikelihood: High
A large share of value creation depends on RenovoCath adoption and expansion into new uses.
Exposure: Product concentration
- Clinical and regulatory execution riskImpact: HighLikelihood: High
Clinical evidence and FDA-cleared use boundaries influence physician confidence and market expansion.
Exposure: TIGeR-PaC and registry studies
- Customer adoption and repeat-order riskImpact: MediumLikelihood: High
Sales depend on hospitals and cancer centers integrating the device into procedures and reordering.
Exposure: Hospital and oncology center customers
- Manufacturing and supply chain dependenceImpact: MediumLikelihood: Medium
RenovoCath is produced by a primary third-party manufacturer, creating supply continuity risk.
Exposure
Accounting
Judgemental itemsRevenue is recorded when the customer obtains control, so delivery terms and order timing affect reported sales.
Impact: Quarterly revenue comparability
Management estimates limited returns for damage or defects, which affects net revenue.
Impact: Net sales and allowances
Changes in warrant valuation create non-cash gains or losses in other income/expense.
Impact: Net loss volatility
Costs tied to clinical trial use were previously expensed in R&D, while commercial units flow through cost of revenue.
Impact: Gross margin and R&D expense
Similar listed companies
Publicly listed companies with a comparable business focus.
Regenerex Pharma, Inc.
Pharmaceutical Preparations
Relay Therapeutics, Inc.
RLAY · Biological Products, (No Diagnostic Substances)
Revolution Medicines, Inc.
RVMD · Biological Products, (No Diagnostic Substances)
Genprex, Inc.
GNPX · Pharmaceutical Preparations
Replimune Group, Inc.
REPL · Biological Products, (No Diagnostic Substances)
Autonomix Medical, Inc.
AMIX · Surgical & Medical Instruments & Apparatus
Last updated: 24/09/2026